BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 22223138)

  • 1. Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells: a novel therapeutic modality.
    Yemelyanov A; Bhalla P; Yang X; Ugolkov A; Iwadate K; Karseladze A; Budunova I
    Cell Cycle; 2012 Jan; 11(2):395-406. PubMed ID: 22223138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells.
    Yemelyanov A; Czwornog J; Gera L; Joshi S; Chatterton RT; Budunova I
    Cancer Res; 2008 Jun; 68(12):4763-73. PubMed ID: 18559523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compound A Inhibits Bladder Cancer Growth Predominantly via Glucocorticoid Receptor Transrepression.
    Zheng Y; Ishiguro H; Ide H; Inoue S; Kashiwagi E; Kawahara T; Jalalizadeh M; Reis LO; Miyamoto H
    Mol Endocrinol; 2015 Oct; 29(10):1486-97. PubMed ID: 26322830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor effect of non-steroid glucocorticoid receptor ligand CpdA on leukemia cell lines CEM and K562.
    Lesovaya EA; Yemelyanov AY; Kirsanov KI; Yakubovskaya MG; Budunova IV
    Biochemistry (Mosc); 2011 Nov; 76(11):1242-52. PubMed ID: 22117551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies.
    Lesovaya E; Yemelyanov A; Kirsanov K; Popa A; Belitsky G; Yakubovskaya M; Gordon LI; Rosen ST; Budunova I
    Cell Cycle; 2013 Jan; 12(1):133-44. PubMed ID: 23255118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer.
    Isikbay M; Otto K; Kregel S; Kach J; Cai Y; Vander Griend DJ; Conzen SD; Szmulewitz RZ
    Horm Cancer; 2014 Apr; 5(2):72-89. PubMed ID: 24615402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Dual Androgen Receptor and Glucocorticoid Receptor Antagonist CB-03-10 as Potential Treatment for Tumors that have Acquired GR-mediated Resistance to AR Blockade.
    Rosette C; Agan FJ; Rosette N; Mazzetti A; Moro L; Gerloni M
    Mol Cancer Ther; 2020 Nov; 19(11):2256-2266. PubMed ID: 32847976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The proteasome inhibitor, bortezomib, induces prostate cancer cell death by suppressing the expression of prostate-specific membrane antigen, as well as androgen receptor.
    Kuroda K; Liu H
    Int J Oncol; 2019 Apr; 54(4):1357-1366. PubMed ID: 30720063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carnosic acid promotes degradation of the androgen receptor and is regulated by the unfolded protein response pathway in vitro and in vivo.
    Petiwala SM; Li G; Bosland MC; Lantvit DD; Petukhov PA; Johnson JJ
    Carcinogenesis; 2016 Aug; 37(8):827-838. PubMed ID: 27267997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells.
    Moriya S; Che XF; Komatsu S; Abe A; Kawaguchi T; Gotoh A; Inazu M; Tomoda A; Miyazawa K
    Int J Oncol; 2013 May; 42(5):1541-50. PubMed ID: 23546223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of the tumor cell death pathway by androgen receptor in response to cytotoxic stimuli.
    Frezza M; Yang H; Dou QP
    J Cell Physiol; 2011 Nov; 226(11):2731-9. PubMed ID: 21448923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined treatment with SAHA, bortezomib, and clarithromycin for concomitant targeting of aggresome formation and intracellular proteolytic pathways enhances ER stress-mediated cell death in breast cancer cells.
    Komatsu S; Moriya S; Che XF; Yokoyama T; Kohno N; Miyazawa K
    Biochem Biophys Res Commun; 2013 Jul; 437(1):41-7. PubMed ID: 23792097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clarithromycin enhances bortezomib-induced cytotoxicity via endoplasmic reticulum stress-mediated CHOP (GADD153) induction and autophagy in breast cancer cells.
    Komatsu S; Miyazawa K; Moriya S; Takase A; Naito M; Inazu M; Kohno N; Itoh M; Tomoda A
    Int J Oncol; 2012 Apr; 40(4):1029-39. PubMed ID: 22200786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors.
    Xie N; Cheng H; Lin D; Liu L; Yang O; Jia L; Fazli L; Gleave ME; Wang Y; Rennie P; Dong X
    Int J Cancer; 2015 Feb; 136(4):E27-38. PubMed ID: 25138562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interference with the androgen receptor protein stability in therapy-resistant prostate cancer.
    Lakshmana G; Baniahmad A
    Int J Cancer; 2019 Apr; 144(8):1775-1779. PubMed ID: 30125354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth.
    Palit SA; Vis D; Stelloo S; Lieftink C; Prekovic S; Bekers E; Hofland I; Šuštić T; Wolters L; Beijersbergen R; Bergman AM; Győrffy B; Wessels LF; Zwart W; van der Heijden MS
    Elife; 2019 Dec; 8():. PubMed ID: 31855178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome inhibition by bortezomib increases IL-8 expression in androgen-independent prostate cancer cells: the role of IKKα.
    Manna S; Singha B; Phyo SA; Gatla HR; Chang TP; Sanacora S; Ramaswami S; Vancurova I
    J Immunol; 2013 Sep; 191(5):2837-46. PubMed ID: 23894194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
    Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ
    J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endostatin inhibits androgen-independent prostate cancer growth by suppressing nuclear receptor-mediated oxidative stress.
    Lee JH; Kang M; Wang H; Naik G; Mobley JA; Sonpavde G; Garvey WT; Darley-Usmar VM; Ponnazhagan S
    FASEB J; 2017 Apr; 31(4):1608-1619. PubMed ID: 28069826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational drug design for androgen receptor and glucocorticoids receptor dual antagonist.
    Wu M; Xie Y; Cui X; Huang C; Zhang R; He Y; Li X; Liu M; Cen S; Zhou J
    Eur J Med Chem; 2019 Mar; 166():232-242. PubMed ID: 30711833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.